{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:36:33Z","timestamp":1787020593583,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-024389"],"award-info":[{"award-number":["INV-024389"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1182950"],"award-info":[{"award-number":["1182950"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The EFFORT clinical trial was conducted in four countries (Cambodia, Ethiopia, Indonesia, and Pakistan) to evaluate the safety and effectiveness of high-dose primaquine (7\u00a0mg\/kg over 7\u00a0days) and single-dose tafenoquine (300\u00a0mg) compared with the standard 14-day low-dose primaquine regimen for the radical cure of patients with\n                    <jats:italic>Plasmodium vivax<\/jats:italic>\n                    malaria. In Indonesia, both regimens were co-administered with dihydroartemisinin\u2013piperaquine. This paper reports on a national stakeholder meeting held in May 2025 to disseminate Indonesia-specific findings and discuss their implications for malaria control and elimination policy. Discussions centred on (i) the evidence gaps regarding tafenoquine when combined with artemisinin combination therapies (ACTs), (ii) the feasibility of implementing high-dose primaquine in Indonesia as a near-term option, and (iii) the need for subnational strategies that reflect the country\u2019s diverse epidemiological context. Stakeholders highlighted the need for further studies on tafenoquine with ACTs, while recognising high-dose primaquine as an immediately implementable option pending strengthened G6PD testing. The discussion emphasised the importance of tailoring strategies to Indonesia\u2019s diverse settings, supported by strong political commitment to elimination.\n                  <\/jats:p>","DOI":"10.1186\/s12936-026-05948-3","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:38:23Z","timestamp":1779878303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dissemination of EFFORT trial results in Indonesia: a stakeholder meeting report on tafenoquine and primaquine for radical cure of Plasmodium vivax"],"prefix":"10.1186","volume":"25","author":[{"given":"Ayodhia Pitaloka","family":"Pasaribu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jimanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Framita","family":"Ainur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novita Rohdearni","family":"Saragih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halik","family":"Hadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedi Sahat Parningotan","family":"Siagian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Budi Junaraman","family":"Sinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari Winasti","family":"Satyagraha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand J.","family":"Laihad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajib","family":"Diptyanusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynold Rizal","family":"Ubra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obet","family":"Tekege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusi","family":"Darmayanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herdiana","family":"Herdiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacklyn","family":"Adella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie","family":"Mannion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne Rini","family":"Poespoprodjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enny","family":"Kenangalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faustina Helena","family":"Burdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Sutanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erni Juwita","family":"Nelwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Jason","family":"Ganadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijaya","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hellen","family":"Mnjala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hellen Dewi","family":"Prameswari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minerva","family":"Theodora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadjar Surya Mensing","family":"Silalahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermawan","family":"Susanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Febry","family":"Immanuella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riskha Tiara","family":"Puspadewi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Budi","family":"Fajariyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iriani","family":"Samad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedy","family":"Supriyanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurul","family":"Muhafilah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmad","family":"Isa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamala","family":"Thriemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"5948_CR1","unstructured":"Ministry of Health RoI: Current situation report on malaria control programme development in Indonesia, 2024 [in Indonesian]. 2024."},{"key":"5948_CR2","unstructured":"Indonesia DGoDPaCMoHoTRo: National Action Plan for Acceleration of Malaria Elimination 2020\u20132026 (Revision). 2023."},{"key":"5948_CR3","unstructured":"Ministry of Health RoI: Malaria case management handbook. 2nd ed. Jakarta: Ministry of Health, Republic of Indonesia; 2023 [in Indonesian]. 2023."},{"key":"5948_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12936-023-04725-w","volume":"22","author":"P Mehdipour","year":"2023","unstructured":"Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, et al. Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. Malar J. 2023;22:306.","journal-title":"Malar J"},{"key":"5948_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002379","volume":"14","author":"NM Douglas","year":"2017","unstructured":"Douglas NM, Poespoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, et al. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study. PLoS Med. 2017;14:e1002379.","journal-title":"PLoS Med"},{"key":"5948_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1473-3099(23)00430-9","volume":"24","author":"RJ Commons","year":"2024","unstructured":"Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, et al. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24:172\u201383.","journal-title":"Lancet Infect Dis"},{"key":"5948_CR7","unstructured":"WHO: WHO guidelines for malaria, 30 November 2024, V8.2. Geneva2024."},{"key":"5948_CR8","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S1473-3099(23)00213-X","volume":"23","author":"I Sutanto","year":"2023","unstructured":"Sutanto I, Soebandrio A, Ekawati LL, Chand K, Noviyanti R, Satyagraha AW, et al. Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. Lancet Infect Dis. 2023;23:1153\u201363.","journal-title":"Lancet Infect Dis"},{"key":"5948_CR9","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83433","author":"JA Watson","year":"2022","unstructured":"Watson JA, Commons RJ, Tarning J, Simpson JA, Llanos Cuentas A, Lacerda MVG, et al. The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis. Elife. 2022. https:\/\/doi.org\/10.7554\/eLife.83433.","journal-title":"Elife"},{"key":"5948_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00265-7","author":"K Thriemer","year":"2023","unstructured":"Thriemer K, Commons RJ. Tafenoquine and artemisinin-based combination therapy for vivax malaria: end of the road or just the beginning? Lancet Infect Dis. 2023. https:\/\/doi.org\/10.1016\/S1473-3099(23)00265-7.","journal-title":"Lancet Infect Dis"},{"key":"5948_CR11","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(19)31285-1","volume":"394","author":"WRJ Taylor","year":"2019","unstructured":"Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394:929\u201338.","journal-title":"Lancet"},{"key":"5948_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-11109-9","volume":"25","author":"SCOPE Study Group","year":"2025","unstructured":"Group SS. High daily dose Short COurse PrimaquinE after G6PD testing for the radical cure of Plasmodium vivax malaria in Indonesia and Papua New Guinea: the SCOPE implementation study protocol. BMC Infect Dis. 2025;25:922.","journal-title":"BMC Infect Dis"},{"key":"5948_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00729-7","author":"TS Degaga","year":"2026","unstructured":"Degaga TS, Pasaribu AP, Tripura R, Ghanchi N, Rajasekhar M, Adhikari B, Ley B, Bamboro SA, Jabbar FA, Hasibuan N et al. Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial. Lancet Infect Dis. 2026. https:\/\/doi.org\/10.1016\/S1473-3099(25)00729-7","journal-title":"Lancet Infect Dis"},{"key":"5948_CR14","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S1473-3099(25)00033-7","volume":"25","author":"V Eng","year":"2025","unstructured":"Eng V, Lek D, Sin S, Feufack-Donfack LB, Orban A, Salvador J, et al. 14 days of high-dose versus low-dose primaquine treatment in patients with Plasmodium vivax infection in Cambodia: a randomised, single-centre, open-label efficacy study. Lancet Infect Dis. 2025;25:884\u201395.","journal-title":"Lancet Infect Dis"},{"key":"5948_CR15","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/infdis\/jit407","volume":"208","author":"AP Pasaribu","year":"2013","unstructured":"Pasaribu AP, Chokejindachai W, Sirivichayakul C, Tanomsing N, Chavez I, Tjitra E, et al. A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. J Infect Dis. 2013;208:1906\u201313.","journal-title":"J Infect Dis"},{"key":"5948_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13412-x","volume":"10","author":"AR Taylor","year":"2019","unstructured":"Taylor AR, Watson JA, Chu CS, Puaprasert K, Duanguppama J, Day NPJ, et al. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nat Commun. 2019;10:5595.","journal-title":"Nat Commun"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05948-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-05948-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05948-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:38:26Z","timestamp":1779878306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-026-05948-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5948"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-05948-3","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"APP, JRP, IS, EJN, FJL and AWS  are members of the Indonesian national treatment guideline committee. RNP participated in the World Health Organization Guideline Development Group on near-patient G6PD tests to support safe and effective\n                      P. vivax\n                      anti-relapse treatment. HH and AD are staff member of WHO. The authors alone are responsible for the views expressed in this publication, which do not necessarily represent the decisions, policies, or views of WHO.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}